Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992798 | 0.79 | — | — | |
| SCHEMBL28330366 | 0.73 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL6494969 | 0.70 | CA2 (0.33) | CA1CA2CA9 | |
| SCHEMBL2274092 | 0.67 | CA2 (0.39) | CA1CA2CA9 | |
| SCHEMBL43258 | 0.66 | — | — | |
| SCHEMBL6495577 | 0.65 | CA2 (0.35) | CA1CA2CA9 | |
| SCHEMBL43239 | 0.65 | — | — | |
| SCHEMBL10369336 | 0.65 | — | — | |
| Bromide SCHEMBL30609919 | 0.63 | — | — | |
| SCHEMBL9710368 | 0.63 | CA2 (0.44) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | CA1 2281/4885CA2 3211/4885CA9 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.